Related Experiment Video
Updated: Jan 9, 2026
09:32
Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach
Published on: September 26, 2019
7.6K
From Pathways to Patients in Atopic Dermatitis: Advanced Systemic Therapies
Alvaro Prados-Carmona1,2,3, Husein Husein-ElAhmed2,4, Francisco José Navarro-Triviño2,5,6
1Department of Dermatology, Hospital Universitario San Cecilio, 18016 Granada, Spain.
International Journal of Molecular Sciences
|December 11, 2025
Summary
Atopic dermatitis management is evolving beyond traditional treatments. Advanced systemic therapies, including monoclonal antibodies and JAK inhibitors, offer personalized strategies for this chronic inflammatory skin disease.
Area of Science:
- Dermatology
- Immunology
- Pharmacology
Background:
- Atopic dermatitis is a prevalent chronic inflammatory skin disease with a substantial burden.
- Current management traditionally relies on topical agents and broad immunosuppressants.
- Recent advancements necessitate an updated understanding of treatment strategies.
Purpose of the Study:
- To review the evolving treatment landscape of atopic dermatitis.
- To explore the transition towards personalized treatment strategies using advanced systemic therapies.
- To provide clinicians with practical guidance on managing atopic dermatitis.
Main Methods:
- Literature review focusing on publications from 2015 onwards.
- Analysis of current and experimental systemic therapies for atopic dermatitis.
- Exploration of key cytokines, receptors, and signaling pathways in type 2 inflammation.
Main Results:
- The treatment paradigm has shifted towards targeted systemic therapies.
- Approved agents include monoclonal antibodies and Janus kinase (JAK) inhibitors.
- Numerous experimental agents are under clinical investigation.
Conclusions:
- Personalized treatment strategies are becoming central to atopic dermatitis management.
- Understanding immunopathogenesis guides the selection of advanced systemic therapies.
- This review synthesizes current knowledge to improve patient outcomes in atopic dermatitis.
Related Concept Videos
01:20Asthma: Pathogenesis and Management
1.2K
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
1.2K
01:19Clinical Applications of Epidermal Stem Cells
3.2K
Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own...
3.2K
01:12Renewal of Skin Epidermal Stem Cells
2.9K
The skin is divided into epidermis, dermis, and hypodermis, the skin's outermost, middle, and inner layers. The human epidermal layer regularly undergoes renewal, where old, dead cells are replaced by new cells. Epidermal stem cells or EpiSCs divide and differentiate to restore the lost cells. For the renewal process, some EpiSCs continuously self-renew. In contrast, few others differentiate into transit-amplifying cells, which later form prickle or spinous cells, followed by granular...
2.9K
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
1.7K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
1.7K
01:20The JAK-STAT Signaling Pathway
11.8K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
11.8K
01:26Asthma-II: Pathophysiology and Classification
4.0K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
4.0K